Phosphodiesterase 5 in the female pig and human urethra: Morphological and functional aspects

BJU International

Volumn 98, Issue 2, 2006, Pages 414-423

  Werkström, Viktoria ^a   Svensson, Anna ^a   Andersson, Karl Erik ^a   Hedlund, Petter ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cGMP; cGMP dependent protein kinase; Cyclic nucleotides; Lower urinary tract; Neurotransmission; Nitric oxide; Smooth muscle

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; LINSIDOMINE; N(G) NITROARGININE; NORADRENALIN; PHENTOLAMINE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PROPRANOLOL; SCOPOLAMINE; SILDENAFIL; TADALAFIL; VARDENAFIL; VIMENTIN;

AGED; ANIMAL TISSUE; ARTICLE; BLADDER; CASE REPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SMOOTH MUSCLE CONTRACTION; SWINE; URETHRA;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MUSCLE, SMOOTH; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; SWINE; URETHRA;

EID: 33745698509     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06217.x     Document Type: Article

References (42)

1. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004; 56: 581-631
2. Andersson KE. Neurotransmission and drug effects in urethral smooth muscle. Scand J Urol Nephrol Suppl 2001; 207: 26-34
3. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001; 108: 671-80
4. Truss MC, Uckert S, Stief CG, Kuczyk M, Jonas U. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization. Urol Res 1996; 24: 123-8
5. Truss MC, Uckert S, Stief CG et al. Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro. Urology 1995; 45: 893-901
6. Uckert S, Kuthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166: 2484-90
7. Mayer M, Stief CG, Truss MC, Uckert S. Phosphodiesterase inhibitors in female sexual dysfunction. World J Urol 2005; 23: 393-7
8. Uckert S, Oelke M, Waldkirch E et al. Cyclic adenosine monophosphate and cyclic guanosine monophosphate-phosphodiesterase isoenzymes in human vagina: relation to nitric oxide synthase isoforms and vasoactive intestinal polypeptide-containing nerves. Urology 2005; 65: 604-10
9. Truss MC, Stief CG, Uckert S et al. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 2001; 19: 344-50
10. Dokita S, Morgan WR, Wheeler MA, Yoshida M, Latifpour J, Weiss RM. NG-nitro-L-arginine inhibits non-adrenergic, non-cholinergic relaxation in rabbit urethral smooth muscle. Life Sci 1991; 48: 2429-36
11. Persson K, Andersson KE. Non-adrenergic, non-cholinergic relaxation and levels of cyclic nucleotides in rabbit lower urinary tract. Eur J Pharmacol 1994; 268: 159-67
12. Boolell M, Allen MJ, Ballard SA et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52
13. Daugan A, Grondin P, Ruault C et al. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H- imidazo[1′,5′:1,6]pyrido[3,4-b]indole-1,3 (2H)-dione analogues. J Med Chem 2003; 46: 4525-32
14. Saenz de Tejada I, Angulo J, Cuevas P et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282-90
15. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90: 836-9
16. Werkström V, Persson K, Ny L, Bridgewater M, Brading AF, Andersson KE. Factors involved in the relaxation of female pig urethra evoked by electrical field stimulation. Br J Pharmacol 1995; 116: 1599-604
17. Werkström V, Alm P, Persson K, Andersson KE. Inhibitory innervation of the guinea-pig urethra; roles of CO, NO and VIP. J Auton Nerv Syst 1998; 74: 33-42
18. Smet PJ, Jonavicius J, Marshall VR, de Vente J. Distribution of nitric oxide synthase-immunoreactive nerves and identification of the cellular targets of nitric oxide in guinea-pig and human urinary bladder by cGMP immunohistochemistry. Neuroscience 1996; 71: 337-48
19. Gillespie JI, Markerink-van Ittersum M, de Vente J. cGMP-generating cells in the bladder wall: identification of distinct networks of interstitial cells. BJU Int 2004; 94: 1114-24
20. Lucas KA, Pitari GM, Kazerounian S et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000; 52: 375-414
21. Sergeant GP, Hollywood MA, McCloskey KD, Thornbury KD, McHale NG. Specialised pacemaking cells in the rabbit urethra. J Physiol 2000; 526: 359-66
22. Werkström V, Ny L, Persson K, Andersson KE. Carbon monoxide-induced relaxation and distribution of haem oxygenase isoenzymes in the pig urethra and oesophagogastric junction. Br J Pharmacol 1997; 120: 312-8
23. Schroder A, Hedlund P, Andersson KE. Carbon monoxide relaxes the female pig urethra as effectively as nitric oxide in the presence of YC-1. J Urol 2002; 167: 1892-6
24. Wheeler MA, Pontari M, Dokita S et al. Age-dependent changes in particulate and soluble guanylyl cyclase activities in urinary tract smooth muscle. Mol Cell Biochem 1997; 169: 115-24
25. Stief CG, Uckert S, Becker AJ et al. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology 2000; 55: 146-50
26. Jeremy JY, Ballard SA, Naylor AM, Miller MA, Angelini GD. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997; 79: 958-63
27. Khan RN, Hamoud H, Warren A, Wong LF, Arulkumaran S. Relaxant action of sildenafil citrate (Viagra) on human myometrium of pregnancy. Am J Obstet Gynecol 2004; 191: 315-21
28. Medina P, Segarra G, Torondel B et al. Inhibition of neuroeffector transmission in human vas deferens by sildenafil. Br J Pharmacol 2000; 131: 871-4
29. Gori T, Sicuro S, Dragoni S, Donati G, Forconi S, Parker JD. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation 2005; 111: 742-6
30. Blount MA, Beasley A, Zoraghi R et al. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 2004; 66: 144-52
31. Corbin JD, Beasley A, Blount MA, Francis SH. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Neurochem Int 2004; 45: 859-63
32. Persson K, Andersson KE. Nitric oxide and relaxation of pig lower urinary tract. Br J Pharmacol 1992; 106: 416-22
33. Thornbury KD, Donaghy KM, Peake J. Characteristics of the NANC post-stimulus ('rebound') contraction of the urinary bladder neck muscle in sheep. Br J Pharmacol 1995; 116: 2451-6
34. Flores-Murrieta FJ, Castaneda-Hernandez G, Granados-Soto V, Herrera JE. Increased bioavailability of sildenafil in Mexican men. JAMA 2000; 283: 1825-6
35. Wibberley A, Nunn PA, Naylor AM, Ramage AG. An investigation of the effects of zaprinast, a PDE inhibitor, on the nitrergic control of the urethra in anaesthetized female rats. Br J Pharmacol 2002; 136: 399-414
36. Burnett AL, Calvin DC, Chamness SL et al. Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans. Nat Med 1997; 3: 571-4
37. Persson K, Pandita RK, Aszodi A et al. Functional characteristics of urinary tract smooth muscles in mice lacking cGMP protein kinase type I. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1112-20
38. Mumtaz FH, Sullivan ME, Thompson CS et al. Alterations in the nitric oxide synthase binding sites and non-adrenergic, non-cholinergic mediated smooth muscle relaxation in the diabetic rabbit bladder outlet: possible relevance to the pathogenesis of diabetic cystopathy. J Urol 1999; 162: 558-66
39. Mumtaz FH, Thompson CS, Khan MA et al. Alterations in the formation of cyclic nucleotides and prostaglandins in the lower urinary tract of the diabetic rabbit. Urol Res 1999; 27: 470-5
40. Masuda H, Tsujii T, Okuno T, Kihara K, Goto M, Azuma H. Involvement of accumulated endogenous NOS inhibitors and decreased NOS activity in the impaired neurogenic relaxation of the rabbit proximal urethra with ischaemia. Br J Pharmacol 2001; 133: 97-106
41. Mitsui T, Kakizaki H, Kobayashi S, Morita H, Matsumura K, Koyanagi T. Vesicourethral function in diabetic patients: association of abnormal nerve conduction velocity with vesicourethral dysfunction. Neurourol Urodyn 1999; 18: 639-45
42. Persson K, Alm P, Johansson K, Larsson B, Andersson KE. Nitric oxide synthase in pig lower urinary tract: immunohistochemistry, NADPH diaphorase histochemistry and functional effects. Br J Pharmacol 1993; 110: 521-30